{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:45:22Z","timestamp":1769161522779,"version":"3.49.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.beha.2021.101244","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T02:11:25Z","timestamp":1610935885000},"page":"101244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel therapeutic targets for chronic myelomonocytic leukemia"],"prefix":"10.1016","volume":"34","author":[{"given":"Terra","family":"Lasho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.beha.2021.101244_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101244_bib2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjh.12756","article-title":"Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review","volume":"165","author":"Patnaik","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2021.101244_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.25684","article-title":"Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management","volume":"95","author":"Patnaik","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.beha.2021.101244_bib4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","article-title":"Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine","volume":"37","author":"Ad\u00e8s","year":"2013","journal-title":"Leuk Res"},{"issue":"13","key":"10.1016\/j.beha.2021.101244_bib5","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2021.101244_bib6","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/ajh.25246","article-title":"Splenectomy in patients with chronic myelomonocytic leukemia: indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients","volume":"93","author":"Pophali","year":"2018","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.beha.2021.101244_bib7","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1038\/bcj.2015.53","article-title":"An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies","volume":"5","author":"Padron","year":"2015","journal-title":"Blood Canc J"},{"issue":"7","key":"10.1016\/j.beha.2021.101244_bib8","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1080\/10428194.2016.1258700","article-title":"Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States","volume":"58","author":"Guru Murthy","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2021.101244_bib9","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1038\/ncomms10767","article-title":"Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.beha.2021.101244_bib10","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Canc Res"},{"issue":"4","key":"10.1016\/j.beha.2021.101244_bib11","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","article-title":"Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.beha.2021.101244_bib12","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview","volume":"102","author":"Sabattini","year":"2010","journal-title":"Pathologica"},{"issue":"10","key":"10.1016\/j.beha.2021.101244_bib13","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/s41375-019-0447-3","article-title":"Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia","volume":"33","author":"Lucas","year":"2019","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.beha.2021.101244_bib14","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1182\/bloodadvances.2020002415","article-title":"Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia","volume":"4","author":"Mangaonkar","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.beha.2021.101244_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.beha.2021.101244_bib16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ajh.23751","article-title":"Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution","volume":"89","author":"Tang","year":"2014","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.beha.2021.101244_bib17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.23846","article-title":"Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study","volume":"89","author":"Wassie","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2021.101244_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Canc Cell"},{"issue":"9","key":"10.1016\/j.beha.2021.101244_bib19","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-018-0157-2","article-title":"Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia","volume":"32","author":"Ernst","year":"2018","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.beha.2021.101244_bib20","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2021.101244_bib21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2011.10","article-title":"Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2021.101244_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia","volume":"151","author":"Gelsi-Boyer","year":"2010","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2021.101244_bib23","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/leu.2009.59","article-title":"Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS\/MPN and AML","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2021.101244_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.23373","article-title":"Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance","volume":"88","author":"Patnaik","year":"2013","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1016\/j.beha.2021.101244_bib25","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.beha.2021.101244_bib26","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood-2011-12-399774","article-title":"Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis","volume":"119","author":"Makishima","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101244_bib27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1471-2407-8-299","article-title":"Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes","volume":"8","author":"Gelsi-Boyer","year":"2008","journal-title":"BMC Canc"},{"issue":"24","key":"10.1016\/j.beha.2021.101244_bib28","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2021.101244_bib29","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101244_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.23345","article-title":"FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"88","author":"Daver","year":"2013","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.beha.2021.101244_bib31","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/leu.2013.97","article-title":"SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML","volume":"27","author":"Laborde","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2021.101244_bib32","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/leu.2013.35","article-title":"SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias","volume":"27","author":"Damm","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2021.101244_bib33","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2013.100","article-title":"An evolutionary perspective on chronic myelomonocytic leukemia","volume":"27","author":"Itzykson","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.beha.2021.101244_bib34","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2021.101244_bib35","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2021.101244_bib36","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2021.101244_bib37","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2021.101244_bib38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.beha.2021.101244_bib39","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2021.101244_bib40","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101244_bib41","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Canc J"},{"issue":"11","key":"10.1016\/j.beha.2021.101244_bib42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11912-019-0855-6","article-title":"Chronic myelomonocytic leukemia: insights into biology, prognostic factors, and treatment","volume":"21","author":"Coltro","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"10.1016\/j.beha.2021.101244_bib43","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2021.101244_bib44","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0145-2126(02)00021-8","article-title":"Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center","volume":"26","author":"Gonz\u00e1lez-Medina","year":"2002","journal-title":"Leuk Res"},{"issue":"33","key":"10.1016\/j.beha.2021.101244_bib45","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2021.101244_bib46","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101244_bib47","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents","volume":"31","author":"Duchmann","year":"2018","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.beha.2021.101244_bib48","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ajh.25488","article-title":"Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients","volume":"94","author":"Coston","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2021.101244_bib49","article-title":"Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome","volume":"5","author":"Patnaik","year":"2015","journal-title":"Blood Canc J"},{"issue":"6","key":"10.1016\/j.beha.2021.101244_bib50","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.beha.2021.101244_bib51","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bmt.1705369","article-title":"Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia","volume":"37","author":"Elliott","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.beha.2021.101244_bib52","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/bmt.2009.375","article-title":"Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience","volume":"45","author":"Krishnamurthy","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2021.101244_bib53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","article-title":"Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"118","author":"Kr\u00f6ger","year":"2002","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.beha.2021.101244_bib54","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2021.101244_bib55","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bmt.2008.366","article-title":"Outcome of allo-SCT for chronic myelomonocytic leukemia","volume":"43","author":"Ocheni","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.beha.2021.101244_bib56","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1038\/bcj.2015.41","article-title":"ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26","volume":"5","author":"Perez Botero","year":"2015","journal-title":"Blood Canc J"},{"issue":"5","key":"10.1016\/j.beha.2021.101244_bib57","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ejh.12073","article-title":"Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"90","author":"Park","year":"2013","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2021.101244_bib58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41408-020-00387-y","article-title":"Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia","volume":"10","author":"Pophali","year":"2020","journal-title":"Blood Canc J"},{"issue":"10","key":"10.1016\/j.beha.2021.101244_bib59","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2021.101244_bib60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101244_bib61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-138680","article-title":"Decitabine versus hydroxyurea for advanced proliferative CMML: results of the Emsco randomized phase 3 Dacota trial","volume":"136","author":"Itzykson","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101244_bib62","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies","volume":"9","author":"Chao","year":"2019","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.beha.2021.101244_bib63","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3324\/haematol.2020.249060","article-title":"To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia","volume":"105","author":"Sallman","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.beha.2021.101244_bib64","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/00498254.2019.1709134","article-title":"Metabolic disposition of H3B-8800, an orally available small-molecule splicing modulator, in rats, monkeys, and humans","volume":"50","author":"Rioux","year":"2020","journal-title":"Xenobiotica"},{"issue":"12","key":"10.1016\/j.beha.2021.101244_bib65","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","volume":"122","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.beha.2021.101244_bib66","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJMc1809507","article-title":"Ivosidenib in IDH1-mutated acute myeloid leukemia","volume":"379","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101244_bib67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood-2020-139492","article-title":"Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study","volume":"136","author":"Garcia","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2021.101244_bib68","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Canc Discov"},{"issue":"12","key":"10.1016\/j.beha.2021.101244_bib69","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Canc Discov"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2021.101244_bib70","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-128909","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent with venetoclax regimens","volume":"134","author":"Maiti","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2021.101244_bib71","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1073\/pnas.90.8.3516","article-title":"MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2","volume":"90","author":"Kozopas","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.beha.2021.101244_bib72","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/sj.onc.1200927","article-title":"Induction of BCL2 family member MCL1 as an early response to DNA damage","volume":"14","author":"Zhan","year":"1997","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.beha.2021.101244_bib73","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/sj.onc.1204142","article-title":"Mcl-1, an early-induction molecule, modulates activin A-induced apoptosis and differentiation of CML cells","volume":"20","author":"Fukuchi","year":"2001","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.beha.2021.101244_bib74","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Aichberger","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2021.101244_bib75","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/s41375-019-0447-3","article-title":"Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia","volume":"33","author":"Lucas","year":"2019","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.beha.2021.101244_bib76","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101244_bib77","series-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis","first-page":"2019","author":"Carr","year":"2019"},{"issue":"8","key":"10.1016\/j.beha.2021.101244_bib78","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-13-1333","article-title":"Molecular pathways: isocitrate dehydrogenase mutations in cancer","volume":"22","author":"Clark","year":"2016","journal-title":"Clin Canc Res"},{"issue":"4","key":"10.1016\/j.beha.2021.101244_bib79","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","article-title":"Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial","volume":"7","author":"Stein","year":"2020","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.beha.2021.101244_bib80","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccr.2008.08.014","article-title":"Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates","volume":"14","author":"Kotecha","year":"2008","journal-title":"Canc Cell"},{"issue":"10","key":"10.1016\/j.beha.2021.101244_bib81","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1101\/gad.297135.117","article-title":"CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies","volume":"31","author":"Lv","year":"2017","journal-title":"Genes Dev"},{"issue":"15","key":"10.1016\/j.beha.2021.101244_bib82","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-15-2781","article-title":"A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML)","volume":"22","author":"Padron","year":"2016","journal-title":"Clin Canc Res"},{"issue":"4","key":"10.1016\/j.beha.2021.101244_bib83","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-01-763219","article-title":"Robust patient-derived xenografts of MDS\/MPN overlap syndromes capture the unique characteristics of CMML and JMML","volume":"130","author":"Yoshimi","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2021.101244_bib84","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to Myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Canc Cell"},{"issue":"6","key":"10.1016\/j.beha.2021.101244_bib85","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nm.4097","article-title":"Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins","volume":"22","author":"Lee","year":"2016","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.beha.2021.101244_bib86","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10637-013-0046-5","article-title":"A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors","volume":"32","author":"Hong","year":"2014","journal-title":"Invest N Drugs"},{"issue":"22","key":"10.1016\/j.beha.2021.101244_bib87","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-13-0485","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors","volume":"19","author":"Eskens","year":"2013","journal-title":"Clin Canc Res"},{"issue":"1","key":"10.1016\/j.beha.2021.101244_bib88","first-page":"56","article-title":"Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches","volume":"16","author":"Brunner","year":"2018","journal-title":"Clin Adv Hematol Oncol : H&O"},{"issue":"S1","key":"10.1016\/j.beha.2021.101244_bib89","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/01.HS9.0000562432.36004.ed","article-title":"PS1034 phase I dose escalation clinical trial OF H3B-8800, a splicing modulator, IN patients with advanced myeloid malignancies","volume":"3","author":"Steensma","year":"2019","journal-title":"HemaSphere"},{"issue":"7","key":"10.1016\/j.beha.2021.101244_bib90","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.2019004352","article-title":"Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia","volume":"136","author":"Patnaik","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2021.101244_bib91","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/art.40420","article-title":"Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor \u03b1 monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis","volume":"70","author":"Burmester","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101244_bib92","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-119302","article-title":"Results from ongoing phase 1\/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed\/refractory chronic myelomonocytic leukemia (CMML)","volume":"132","author":"Patnaik","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2021.101244_bib93","article-title":"Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2021.101244_bib94","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/0008-5472.CAN-11-3468","article-title":"Impaired IFN-\u03b1 production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression","volume":"72","author":"Sisirak","year":"2012","journal-title":"Canc Res"},{"issue":"3","key":"10.1016\/j.beha.2021.101244_bib95","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2007-01-067546","article-title":"CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)","volume":"110","author":"Kordasti","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101244_bib96","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/leu.2008.333","article-title":"Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS)","volume":"23","author":"Kotsianidis","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2021.101244_bib97","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1062208","article-title":"Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome","volume":"5","author":"Kittang","year":"2016","journal-title":"OncoImmunology"},{"issue":"7","key":"10.1016\/j.beha.2021.101244_bib98","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.beha.2021.101244_bib99","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2021.101244_bib100","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1172\/JCI21583","article-title":"Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes","volume":"114","author":"Munn","year":"2004","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.beha.2021.101244_bib101","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ni.2077","article-title":"Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells","volume":"12","author":"Pallotta","year":"2011","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/j.beha.2021.101244_bib102","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.4049\/jimmunol.181.8.5396","article-title":"The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation","volume":"181","author":"Chen","year":"2008","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.beha.2021.101244_bib103","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"Ido in the tumor microenvironment: inflammation, counter-regulation, and tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol"},{"issue":"5380","key":"10.1016\/j.beha.2021.101244_bib104","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1126\/science.281.5380.1191","article-title":"Prevention of allogeneic fetal rejection by tryptophan catabolism","volume":"281","author":"Munn","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.beha.2021.101244_bib105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ccell.2017.11.012","article-title":"Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity","volume":"33","author":"Kunimoto","year":"2018","journal-title":"Canc Cell"},{"issue":"1","key":"10.1016\/j.beha.2021.101244_bib106","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tranon.2016.10.003","article-title":"PLK1, A potential target for cancer therapy","volume":"10","author":"Liu","year":"2017","journal-title":"Transl Oncol"},{"issue":"10","key":"10.1016\/j.beha.2021.101244_bib107","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/pbc.25081","article-title":"Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia","volume":"61","author":"Caldwell","year":"2014","journal-title":"Pediatr Blood Canc"},{"issue":"6","key":"10.1016\/j.beha.2021.101244_bib108","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/bjh.15204","article-title":"Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed\/refractory acute myeloid leukaemia","volume":"184","author":"Ottmann","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2021.101244_bib109","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2217\/fon.14.53","article-title":"Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development","volume":"10","author":"Janning","year":"2014","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.beha.2021.101244_bib110","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","article-title":"Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy","volume":"124","author":"D\u00f6hner","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.beha.2021.101244_bib111","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-20-2586","article-title":"A phase Ib study of onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia","volume":"26","author":"Zeidan","year":"2020","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.beha.2021.101244_bib112","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4419-9967-2_1","article-title":"DNA methyltransferases, DNA damage repair, and cancer","volume":"754","author":"Jin","year":"2013","journal-title":"Adv Exp Med Biol"},{"issue":"15_suppl","key":"10.1016\/j.beha.2021.101244_bib113","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.7506","article-title":"Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)\/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777)","volume":"38","author":"Ades","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:27Z","timestamp":1761498387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692621000050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1521692621000050"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2021.101244","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutic targets for chronic myelomonocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2021.101244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101244"}}